Research Shows Pacific Edge’s Cxbladder Detect Outperforms Other Non-Invasive Bladder Cancer Diagnostics
Dunedin, NZ and Hershey, PA (May 25, 2015): Newly published research demonstrates that Cxbladder out performs other
non-invasive bladder cancer diagnostics, announced Pacific Edge, Ltd. The new research comparing and ranking four widely
used tests was published online this week in the peer-reviewed Open Access medical journal BioMed Central (“BMC”)
Medical Research Methodology. http://www.biomedcentral.com/1471-2288/15/45
. Pacific Edge, a New Zealand-headquartered global cancer diagnostics company with U.S. subsidiary, Pacific Edge
Diagnostics USA, in Hershey, PA, developed and markets Cxbladder.
“The published research reviewed the performance of Cxbladder Detect versus other available non-invasive test methods,
based on data from 939 patients and 5 clinical trials, and showed Cxbladder Detect to outperform those methods,
including the UroVysion® FISH assay that is widely used in the United States in conjunction with standard procedures in
the urlogical work-up for bladder cancer,” said David Darling, Pacific Edge Chief Executive Officer. “These new findings
favourably position Cxbladder Detect as the leading non-invasive bladder cancer diagnostic tool in terms of its relative
performance (high sensitivity, high signal-to-noise, and low cross-validation error rate).” The other non-invasive test
methods included in the comparison were cytology and NMP22.
(Ms.) Jackie Walker, Chief Executive Officer for Pacific Edge Diagnostics USA, said, “These results should be highly
relevant for both urologists and US payer organizations who provide reimbursement for cancer diagnostic tests. This
publication is the first piece of comparative data that includes UroVysion® FISH, a molecular test that is widely used
by clinicians and physicians in the US and reimbursed by most major payers.”
“This and other recent peer-reviewed publications demonstrating the superiority of Cxbladder represent key elements in
our company’s strategy of delivering physicians a one-stop shop for bladder cancer detection with high performance
Cxbladder products in conjunction with standard procedures for bladder cancer detection and surveillance,” concluded
David Darling.
ABOUT Cxbladder Detect
Cxbladder Detect is a proprietary, accurate molecular diagnostic test that enables the non-invasive detection of bladder
and other urinary tract cancers from a small volume of urine.
Cxbladder Detect is commercially available in New Zealand, Australia and the USA. Cxbladder Detect is available in the
USA and NZ as a laboroatory Developed Test (LDT) from the company’s CLIA certified laboratories, providing physicians
and clinicians with a quick, cost effective and accurate measure of the presence of the cancer, and provides urologists
with a reliable adjunct to cystoscopy. The Cxbladder Detect cancer detection test has been validated by a multicentre,
international clinical study. www.Cxbladder.com
ABOUT Cxbladder Triage
Cxbladder Triage is a novel molecular test that combines the power of the genomic biomarkers with extra phenotypic
biomarkers to accurately identify and remove patients with haematuria who have a low probability of bladder cancer, from
needing to have a full-urological work-up.
This is a tool for use by clinicians and physicians in the primary evaluation and is intended to reduce of the number of
patients needing a full expensive and invasive work-up for urothelial cancer. www.Cxbladder.com
ends